Developer docs
API playgroundTry for free, no card

Search company profiles

Quanterix

Full company profile

uuid003ie6g

Namestring
Quanterix
Legal namestring
Quanterix Corporation
Company typeenum
Public
Founded yearint
2007
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBillerica, United States
HQ citystring
Billerica
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
blood-based diagnostics, Alzheimer's biomarkers, immunoassay technology, clinical laboratory services, neurodegenerative disease testing
Industry3 codes
PRIMARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAB
Immunoassay Diagnostics (ELISA, chemiluminescence, serology)
NAICS code3 codes
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • Services-Medical Laboratories8071
  • Laboratory Analytical Instruments3826
Product category
Clinical Diagnostics — Alzheimer's Disease Blood-Based Biomarker Testing
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Laboratory Testing Services
TypeTransaction Fee
Description

Blood-based biomarker tests ordered by healthcare providers and processed at CLIA-certified laboratory in Billerica, MA. Revenue generated through insurance billing and self-pay patient options. Insurance coverage varies by payer; some may cover for patients with cognitive symptoms.

lucentdiagnostics.com
2Provider Portal Services
TypeSubscription Recurring
Description

Electronic portal for requisition, ordering, tracking and reporting of biomarker tests. Providers pay fees as set forth on the portal for test kits and services.

lucentdiagnostics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details2 tiers
1Insurance-covered testing for eligible patients
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

Coverage varies by payer; some insurers may cover for patients with cognitive symptoms. Provider is responsible for billing health plans.

lucentdiagnostics.com
2Self-pay/cash pay testing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Test purchase may be made by Provider or Provider's patient. Pricing depends on patient qualifications. Patient Financial Assistance Program available.

lucentdiagnostics.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1LucentAD
Description

Blood-based biomarker tests for Alzheimer's disease detection, including LucentAD Complete and LucentAD p-Tau 217 products.

lucentdiagnostics.com
+2 more records
Core offering1 text field

Quanterix operates through its Lucent Diagnostics brand to provide blood-based biomarker testing for Alzheimer's disease using its proprietary Simoa (Single Molecule Array) ultra-sensitive detection technology. The company runs a CLIA-certified laboratory that processes biomarker tests ordered by healthcare providers and partners, including LucentAD Complete and LucentAD p-Tau 217 assays. It also partners with pharmaceutical companies and screening services to expand access to early Alzheimer's detection.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 90% sensitivity, 90% specificity, 90% accuracy for LucentAD Complete
+4 more records
Product overview1 text field

Quanterix, through its Lucent Diagnostics brand, offers a portfolio of blood-based biomarker tests for Alzheimer's disease assessment powered by Simoa ultra-sensitive technology. The product line includes LucentAD Complete (a multi-analyte panel measuring p-Tau 217, Aß42/40, GFAP, and NfL) and LucentAD p-Tau 217 (a single-biomarker test), both using Simoa technology for biomarker detection at femtogram-level sensitivity.

Product and service2 records
1LucentAD Complete
CategoryClinical Diagnostic Test
2LucentAD p-Tau 217
CategoryClinical Diagnostic Test
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-02
Description

Lucent Diagnostics partnered with Life Line Screening to offer non-invasive blood-based biomarker tests nationally. Life Line Screening deploys Lucent's tests through its network of over 15,000 community events annually across Florida, California, and Texas. This collaboration expands access to diagnostic testing outside clinical settings, serving both metropolitan and rural communities and addressing the estimated 7 million Americans living with Alzheimer's.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-10-24
Description

LucentAD p-Tau 217 leverages Quanterix's ultra-sensitive Simoa technology combined with J&J Innovative Medicine's extensively studied p-Tau 217 antibodies to provide high accuracy with a simplified workflow. This antibody licensing enables the high-performance assay with proven correlation to amyloid pathology.

3Banyan Biomarkers, Inc.
Strategic tierCoreTypeTechnology or Integration
Description

GFAP biomarker is offered pursuant to a license from Banyan Biomarkers, Inc. Banyan GFAP is a registered trademark of Banyan Biomarkers. This licensing agreement enables the multi-analyte panel in LucentAD Complete.

lucentdiagnostics.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Peers10 records
TypeEmerging player
Description

Bio-Techne provides protein biomarker reagents, ELISA kits, and Ella automated immunoassay instruments that partially overlap with Quanterix's research-use offerings. While broader in scope, Bio-Techne serves pharma and academic biomarker research customers similar to Quanterix's research segment.

TypeEmerging player
Description

SomaLogic's SomaScan proteomics platform provides ultra-sensitive protein biomarker measurement that partially overlaps with Simoa's research-use applications. Both serve pharma/biotech biomarker discovery and validation, though with different underlying technologies.

TypeDirect peer
Description

C2N Diagnostics offers PrecivityAD, a blood-based test for Alzheimer's amyloid pathology that directly competes with LucentAD p-Tau 217 and LucentAD Complete. Both companies target the same provider and patient segments with non-invasive, blood-based alternatives to PET imaging and CSF testing.

TypeBroad incumbent
Description

Eli Lilly markets Kisunla, an FDA-approved Alzheimer's therapy, and is developing companion blood-based diagnostics that overlap with Quanterix's biomarker testing use cases. While a pharma company, Lilly's diagnostic efforts make it a competitor in AD risk assessment pathways.

TypeBroad incumbent
Description

Roche's Elecsys p-Tau 217 plasma test for Alzheimer's competes with LucentAD on installed immunoassay analyzers in hospital and reference labs globally. Roche offers overlapping biomarker capability as part of its broad diagnostics portfolio, leveraging existing customer relationships and payer contracts.

6Beckman Coulter Diagnostics
TypeBroad incumbent
Description

Beckman Coulter's DxI and Access immunoassay analyzers serve hospital and reference labs with overlapping biomarker testing capabilities. As a broad diagnostics incumbent, Beckman Coulter represents a channel and capability competitor in clinical lab biomarker testing.

TypeBroad incumbent
Description

Siemens Healthineers offers the ADVIA Centaur and Atellica immunoassay platforms that compete with Quanterix's clinical diagnostic positioning. As a broad incumbent with established hospital lab relationships, Siemens represents a channel competitor in blood-based biomarker testing.

TypeDirect peer
Description

Meso Scale Diagnostics offers the S-Plex and QuickPlex ultra-sensitive electrochemiluminescence immunoassay platforms that compete with Quanterix's Simoa technology in research and clinical trial biomarker applications. Both target pharma/biotech research customers with high-sensitivity multiplex biomarker detection.

9Abbott Diagnostics
TypeBroad incumbent
Description

Abbott's Alinity ci series and ARCHITECT immunoassay platforms provide biomarker testing infrastructure that competes broadly with Quanterix's clinical lab services. Abbott's installed base in hospitals globally represents a channel alternative for blood-based Alzheimer's testing.

10Fujirebio
TypeDirect peer
Description

Fujirebio's Lumipulse G p-Tau 217/β-Amyloid 1-42 plasma ratio test is a direct competitor in blood-based Alzheimer's diagnostics with FDA breakthrough designation. Both companies leverage immunoassay platforms to deliver plasma-based amyloid pathology assessment for clinical use.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Quanterix

Clinical Diagnostics — Alzheimer's Disease Blood-Based Biomarker Testinglucentdiagnostics.com

Quanterix firmographics

Firmographics
Name
Quanterix
Legal name
Quanterix Corporation
Website
https://lucentdiagnostics.com
Company type
Public
Founded year
2007
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Quanterix industry classification

Industry
Product category
Clinical Diagnostics — Alzheimer's Disease Blood-Based Biomarker Testing
NAICS
Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
SIC
Services-Medical Laboratories (8071), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAB
Immunoassay Diagnostics (ELISA, chemiluminescence, serology)

Keywords

  • Blood-based diagnostics
  • Alzheimer's biomarkers
  • Immunoassay technology
  • Clinical laboratory services
  • Neurodegenerative disease testing

Where Quanterix is headquartered

Location

Headquarters

HQ city
Billerica
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Quanterix business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Laboratory Testing Services: Blood-based biomarker tests ordered by healthcare providers and processed at CLIA-certified laboratory in Billerica, MA. Revenue generated through insurance billing and self-pay patient options. Insurance coverage varies by payer; some may cover for patients with cognitive symptoms.
  2. Provider Portal Services: Electronic portal for requisition, ordering, tracking and reporting of biomarker tests. Providers pay fees as set forth on the portal for test kits and services.

Pricing tiers

ModelBillingPrice
Transaction based/ take ratePay-as-you-goInsurance-covered testing for eligible patients
Unit PricingPay-as-you-goSelf-pay/cash pay testing

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Quanterix product offering

Product offering

Core offering

Quanterix operates through its Lucent Diagnostics brand to provide blood-based biomarker testing for Alzheimer's disease using its proprietary Simoa (Single Molecule Array) ultra-sensitive detection technology. The company runs a CLIA-certified laboratory that processes biomarker tests ordered by healthcare providers and partners, including LucentAD Complete and LucentAD p-Tau 217 assays. It also partners with pharmaceutical companies and screening services to expand access to early Alzheimer's detection.

Product overview

Quanterix, through its Lucent Diagnostics brand, offers a portfolio of blood-based biomarker tests for Alzheimer's disease assessment powered by Simoa ultra-sensitive technology. The product line includes LucentAD Complete (a multi-analyte panel measuring p-Tau 217, Aß42/40, GFAP, and NfL) and LucentAD p-Tau 217 (a single-biomarker test), both using Simoa technology for biomarker detection at femtogram-level sensitivity.

Differentiator

Problem solved

Functional benefit

Brands

  • LucentAD: Blood-based biomarker tests for Alzheimer's disease detection, including LucentAD Complete and LucentAD p-Tau 217 products.
  • Simoa
  • Simoa HD-X

Products and services

  • LucentAD Complete
  • LucentAD p-Tau 217

Quantifiable outcome

  • 90% sensitivity, 90% specificity, 90% accuracy for LucentAD Complete
  • +4 more outcomes

Companies that use Quanterix

Customer profile

Named customers6 records

Segments5 records

Ideal customer profiles3 records

Quanterix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Quanterix partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Life Line ScreeningcoreChannel Partner/ Reseller/ Distributor · 2 March 2026Lucent Diagnostics partnered with Life Line Screening to offer non-invasive blood-based biomarker tests nationally. Life Line Screening deploys Lucent's tests through its network of over 15,000 community events annually across Florida, California, and Texas. This collaboration expands access to diagnostic testing outside clinical settings, serving both metropolitan and rural communities and addressing the estimated 7 million Americans living with Alzheimer's.
  • Johnson & Johnson Innovative MedicinecoreTechnology or Integration · 24 October 2023LucentAD p-Tau 217 leverages Quanterix's ultra-sensitive Simoa technology combined with J&J Innovative Medicine's extensively studied p-Tau 217 antibodies to provide high accuracy with a simplified workflow. This antibody licensing enables the high-performance assay with proven correlation to amyloid pathology.
  • Banyan Biomarkers, Inc.coreTechnology or IntegrationGFAP biomarker is offered pursuant to a license from Banyan Biomarkers, Inc. Banyan GFAP is a registered trademark of Banyan Biomarkers. This licensing agreement enables the multi-analyte panel in LucentAD Complete.

Scale indicators6 records

Recent moves6 records

Quanterix competitors and assessment

Company assessment

Emerging players

  • Bio-Techne: Bio-Techne provides protein biomarker reagents, ELISA kits, and Ella automated immunoassay instruments that partially overlap with Quanterix's research-use offerings. While broader in scope, Bio-Techne serves pharma and academic biomarker research customers similar to Quanterix's research segment.
  • SomaLogic: SomaLogic's SomaScan proteomics platform provides ultra-sensitive protein biomarker measurement that partially overlaps with Simoa's research-use applications. Both serve pharma/biotech biomarker discovery and validation, though with different underlying technologies.

Direct peers

  • C2N Diagnostics: C2N Diagnostics offers PrecivityAD, a blood-based test for Alzheimer's amyloid pathology that directly competes with LucentAD p-Tau 217 and LucentAD Complete. Both companies target the same provider and patient segments with non-invasive, blood-based alternatives to PET imaging and CSF testing.
  • Meso Scale Diagnostics: Meso Scale Diagnostics offers the S-Plex and QuickPlex ultra-sensitive electrochemiluminescence immunoassay platforms that compete with Quanterix's Simoa technology in research and clinical trial biomarker applications. Both target pharma/biotech research customers with high-sensitivity multiplex biomarker detection.
  • Fujirebio: Fujirebio's Lumipulse G p-Tau 217/β-Amyloid 1-42 plasma ratio test is a direct competitor in blood-based Alzheimer's diagnostics with FDA breakthrough designation. Both companies leverage immunoassay platforms to deliver plasma-based amyloid pathology assessment for clinical use.

Broad incumbents

  • Eli Lilly: Eli Lilly markets Kisunla, an FDA-approved Alzheimer's therapy, and is developing companion blood-based diagnostics that overlap with Quanterix's biomarker testing use cases. While a pharma company, Lilly's diagnostic efforts make it a competitor in AD risk assessment pathways.
  • Roche Diagnostics: Roche's Elecsys p-Tau 217 plasma test for Alzheimer's competes with LucentAD on installed immunoassay analyzers in hospital and reference labs globally. Roche offers overlapping biomarker capability as part of its broad diagnostics portfolio, leveraging existing customer relationships and payer contracts.
  • Beckman Coulter Diagnostics: Beckman Coulter's DxI and Access immunoassay analyzers serve hospital and reference labs with overlapping biomarker testing capabilities. As a broad diagnostics incumbent, Beckman Coulter represents a channel and capability competitor in clinical lab biomarker testing.
  • Siemens Healthineers: Siemens Healthineers offers the ADVIA Centaur and Atellica immunoassay platforms that compete with Quanterix's clinical diagnostic positioning. As a broad incumbent with established hospital lab relationships, Siemens represents a channel competitor in blood-based biomarker testing.
  • Abbott Diagnostics: Abbott's Alinity ci series and ARCHITECT immunoassay platforms provide biomarker testing infrastructure that competes broadly with Quanterix's clinical lab services. Abbott's installed base in hospitals globally represents a channel alternative for blood-based Alzheimer's testing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Quanterix social profiles

Digital presence

Quanterix compliance and trust

Trust signal

Compliance2 records

Quanterix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Quanterix leadership team

Management profile

Number of profiles

Profiles3 records

Quanterix subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Quanterix funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Quanterix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quanterix

What does Quanterix do?

Quanterix operates through its Lucent Diagnostics brand to provide blood-based biomarker testing for Alzheimer's disease using its proprietary Simoa (Single Molecule Array) ultra-sensitive detection technology. The company runs a CLIA-certified laboratory that processes biomarker tests ordered by healthcare providers and partners, including LucentAD Complete and LucentAD p-Tau 217 assays. It also partners with pharmaceutical companies and screening services to expand access to early Alzheimer's detection.

Is Quanterix a public or private company?

Quanterix is a public company. It is classified as public and is currently operating.

When was Quanterix founded?

Quanterix was founded in 2007. It employs 1 to 10 people.

Where is Quanterix based?

Quanterix is headquartered in Billerica, United States, in the North America region.

How does Quanterix make money?

Two revenue lines are on record. Laboratory Testing Services are the primary driver. The others are provider Portal Services.

Who are Quanterix's main competitors?

Emerging players on record are Bio-Techne and SomaLogic. Direct peers are C2N Diagnostics, Meso Scale Diagnostics and Fujirebio. Broad incumbents are Eli Lilly, Roche Diagnostics, Beckman Coulter Diagnostics, Siemens Healthineers and Abbott Diagnostics.

Does Quanterix have an API?

No public API is recorded for Quanterix.

What industry is Quanterix in?

Quanterix's product category is Clinical Diagnostics — Alzheimer's Disease Blood-Based Biomarker Testing. Its primary akta.pro industry code is HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry), with a secondary code of HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals